Cargando…

Biomarkers predictive of response to pembrolizumab in head and neck cancer

BACKGROUND: We performed an integrated biomarker evaluation in pembrolizumab‐treated patients with R/M HNSCC enrolled in KEYNOTE‐012 or KEYNOTE‐055. The relationship between biomarkers and HPV status was explored. METHODS: We evaluated PD‐L1 (combined positive score [CPS]), TMB, T‐cell‐inflamed gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pfister, David G., Haddad, Robert I., Worden, Francis P., Weiss, Jared, Mehra, Ranee, Chow, Laura Q. M., Liu, Stephen V., Kang, Hyunseok, Saba, Nabil F., Wirth, Lori J., Sukari, Ammar, Massarelli, Erminia, Ayers, Mark, Albright, Andrew, Webber, Andrea L., Mogg, Robin, Lunceford, Jared, Huang, Lingkang, Cristescu, Razvan, Cheng, Jonathan, Seiwert, Tanguy Y., Bauml, Joshua M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067081/ https://www.ncbi.nlm.nih.gov/pubmed/36479637 http://dx.doi.org/10.1002/cam4.5434

Ejemplares similares

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
por: Haddad, Robert I, et al.
Publicado: (2022)

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
por: Cristescu, Razvan, et al.
Publicado: (2022)

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
por: Ayers, Mark, et al.
Publicado: (2015)

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
por: Cristescu, Razvan, et al.
Publicado: (2022)

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
por: Mehra, Ranee, et al.
Publicado: (2018)

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
por: Chow, Laura Q.M., et al.
Publicado: (2016)

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
por: Garassino, Marina C., et al.
Publicado: (2022)

Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date
por: McCusker, Michael G, et al.
Publicado: (2020)

Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)
por: Jung, Kyungsuk, et al.
Publicado: (2018)

2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors
por: Naidoo, Jarushka, et al.
Publicado: (2018)

Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas
por: Ho, Won Jin, et al.
Publicado: (2018)

Preclinical to clinical translation of anti-PD-1 blockade
por: Hirsch, Heather, et al.
Publicado: (2015)

Molecular targeted therapies in head and neck cancer - An update of recent developements -
por: Goerner, Martin, et al.
Publicado: (2010)

Association between Immunosuppressive Therapy Utilized in the Treatment of Autoimmune Disease or Transplant and Cancer Progression
por: Reyes, Amanda, et al.
Publicado: (2022)

Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?
por: Reyes, Amanda, et al.
Publicado: (2023)

Level of phosphohistone H3 among various types of human cancers
por: Sun, Amy, et al.
Publicado: (2012)

Diagnosis difficulties in a patient with progressive loss of vision - a case report
por: Cristescu, Teodor Razvan
Publicado: (2017)

Acute Pancreatitis Secondary to Pembrolizumab-Induced Hypertriglyceridemia
por: Ashfaq, Ammar, et al.
Publicado: (2023)

Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test
por: Cristescu, Razvan, et al.
Publicado: (2022)

ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
por: Johnson, Melissa, et al.
Publicado: (2022)

Radiation Recall Dermatitis Following Treatment With Pembrolizumab: A Case Report and Review of the Literature
por: Sandhu, Michael, et al.
Publicado: (2023)

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
por: Aggarwal, Charu, et al.
Publicado: (2023)

Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions
por: Pathak, Ranjan, et al.
Publicado: (2021)

Characterization of Carbon-Black-Based Nanocomposite Mixtures of Varying Dispersion for Improving Stochastic Model Fidelity
por: Albright, Tyler, et al.
Publicado: (2023)

Investigating the Electromechanical Properties of Carbon Black-Based Conductive Polymer Composites via Stochastic Modeling
por: Albright, Tyler, et al.
Publicado: (2023)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

Biomarkers in immunotherapy: literature review and future directions
por: Pharaon, Rebecca, et al.
Publicado: (2020)

Clinical Activity of Selpercatinib in RET Mutant Pheochromocytoma-Case Reports
por: Konda, Bhavana, et al.
Publicado: (2021)

Oscillatory Correlates of Selective Restudy
por: Wirth, Michael, et al.
Publicado: (2021)

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
por: Gong, Jun, et al.
Publicado: (2018)

Eyelid laxity and sleep apnea syndrome: a review
por: Cristescu Teodor, Razvan, et al.
Publicado: (2019)

Ocular pathology associated with obstructive sleep apnea syndrome
por: Cristescu, Teodor Răzvan, et al.
Publicado: (2020)

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
por: Tejani, Mohamedtaki A, et al.
Publicado: (2010)

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
por: Läubli, Heinz, et al.
Publicado: (2015)

Pembrolizumab for all
por: Kim, Myung S., et al.
Publicado: (2022)

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2023)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
por: Pathak, Ranjan, et al.
Publicado: (2020)

Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy
por: Murakami, Shuji, et al.
Publicado: (2020)

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Pembrolizumab-associated sarcoidosis
por: Cotliar, Jonathan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0pel7i0jeoq1aaksmq1kfkqdek